eligibility_summary
Include resectable stage II–IIIB (N2) NSCLC without EGFR/ALK as primary therapy, operable, able to receive neoadjuvant pembrolizumab + platinum, for adjuvant: no pCR, PD‑L1/TROP2 tested on resection, disease‑free, toxicities recovered, controlled HIV/HBV/HCV. Exclude prohibited histologies/locations, significant neurologic/ocular/GI/cardiac disease, recent therapies/vaccines/trials, immunosuppression, other malignancy, active autoimmune/ILD/infection, viral coinfection/transplant, poor recovery, allergy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: Adjuvant pembrolizumab ± sacituzumab tirumotecan (MK‑2870/SKB264) after surgery in resectable Stage II–IIIB (N2) NSCLC lacking pCR post‑neoadjuvant pembrolizumab + platinum doublet. Tested interventions and mechanisms: 1) Pembrolizumab (MK‑3475) is a monoclonal antibody immune checkpoint inhibitor targeting PD‑1 on T cells, blocking PD‑1/PD‑L1 signaling to restore antitumor T‑cell activity. Type: biologic mAb. 2) Sacituzumab tirumotecan is a TROP2‑directed antibody‑drug conjugate, the anti‑TROP2 mAb delivers a cleavable topoisomerase I inhibitor payload into TROP2‑expressing tumor cells, causing DNA damage and bystander cytotoxicity. Type: ADC. Targeted cells/pathways: PD‑1 checkpoint on activated T cells, PD‑L1/PD‑1 axis, TROP2 on epithelial tumor cells, topoisomerase I–mediated DNA replication. Neoadjuvant chemo backbones (platinum, pemetrexed/gemcitabine/paclitaxel) act via DNA damage or microtubules.